Inducible Expression Cassette with AARE Promoter for Controlled Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches lack targeted and controlled expression systems for therapeutic genes, leading to non-specific and prolonged expression, which can result in side effects and reduced efficacy.
Innovation Solution
An inducible expression cassette comprising a C/EBP-ATF responsive element with an Amino Acid Response Element (AARE) sequence, linked to a minimal thymidine kinase promoter, allows for controlled expression of a gene of interest in response to amino acid deficiencies, specifically activating transcription in targeted cell types and durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If constitutive expression vectors are used to deliver therapeutic genes, then gene delivery efficiency is improved, but expression cannot be limited to specific cell types or time periods, leading to non-specific and prolonged expression with potential side effects
Solution Approach 1:
The patent employs a dynamic promoter system that can switch between inactive and active states based on amino acid availability. The promoter contains AARE sequences that respond to amino acid starvation signals, allowing the expression system to adapt its activity level according to cellular metabolic conditions rather than maintaining constant constitutive expression
Solution Approach 2:
The invention changes the regulatory parameter of gene expression from constitutive (always on) to inducible (condition-dependent). By incorporating AARE response elements into the promoter, the system's expression level becomes a variable parameter that changes in response to amino acid availability, enabling controlled and targeted therapeutic gene expression
2Reliability
If inducible expression systems are used to limit expression to given cell types and time periods, then targeted and non-toxic therapy is improved, but basal level expression remains too high, causing side effects
Solution Approach 1:
The patent extracts and utilizes a specific regulatory mechanism (AARE sequences) that responds to amino acid starvation conditions. By isolating this specific response element and incorporating it into the promoter, the system achieves ultra-low basal expression that only activates under defined inducible conditions, effectively removing the harmful basal expression component while preserving targeted therapy capabilities
3Adaptability or versatility
If current inducible systems are used, then some level of control is achieved, but they lack specificity and ease of activation, requiring complex mechanisms
Solution Approach 1:
The patent employs a self-service induction mechanism where the cell's own metabolic state (amino acid availability) directly controls gene expression through the AARE promoter. The system automatically senses cellular nutritional status and activates therapeutic gene expression without requiring external complex induction mechanisms, making the system both simple and highly adaptable to physiological conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system enables precise and reversible gene expression with low basal levels, minimizing side effects and optimizing therapeutic outcomes for diseases such as proliferative, infectious, neurological, and cardiovascular conditions by using an amino acid-deficient diet to induce gene expression.
Implementation Method 1
The invention relates to an inducible expression cassette comprising a CARE (C/EBP-ATF Responsive Element) regulatory sequence containing an AARE (Amino Acid Response Element) sequence
Data Source
AI summary
The invention relates to an expression cassette including a gene of interest under the control of an inducible promoter, characterized in that said inducible promoter includes at least one CARE regulatory sequence (C/EBP-ATF responsive element) and a minimal promoter. The invention also relates to a vector and a host cell, as well as to a pharmaceutical composition including such a cassette, and to the use thereof for treating diseases by gene therapy.